Cancer

Please Note: The technologies listed here are not available to the public at this time. These technologies are in the early stages of research and require further development before they are ready for the marketplace. The VA is currently in the process of identifying potential companies who may be interested in licensing and/or further developing the technology through Cooperative Research and Development Agreements (CRADA). Through cooperative research initiatives such as these, it is our hope and goal that commercial products will be fully developed and made available to benefit veterans and others.

Navigate This Topic:

Cancer


Date Posted

Reference No.

Patent No.

Title

08/06/2008

08-038

Administration of Nanodrugs in Proper Menstrual Stage for Maximal Drug Retention in Breast Cancer

07/23/2008

06-123

Use of Inhibitors of P-Selectin in Inhibition of Angiogenesis in Diseases Characterized by Female Preponderance

05/13/2004

04-002

Chronic Lymphocytic Leukemia Treatment

10/22/2003

03-080

A Novel Specific Inhibitor of the Cyclin Kinase Inhibitor p21 and Methods of Using the Inhibitor (breast cancer application)

03/29/2004

03-079

Macrophage Migration Inhibitory Factor: A Novel Diagnostic for Urological Inflammatory Disease and Cancer

05/30/2003

03-044

7,361,474

Diagnosis and Monitoring of Prostate Cancer Patients by Measurement of Serum Macrophage Migration Inhibitory Factor.

04/18/2002

01-110

7,049,410

Antibodies to a Novel EGF Receptor Related Protein (ERRP)

03/20/2002

01-053

A Novel Specific Inhibitor of the Cyclin Kinase Inhibitor

04/12/2002

00-033

Neu Differentiation Factor-Beta (NFD-ß), a Potent Inhibitor of Angiogenesis and a Schwann-Cell Derived Factor Capable of Inducing Differentiation in Human Neuroblastoma Tumor Cells

03/22/2002

99-013

6,399,743
6,582,934

ERRP, A newly isolated CDNA (EGF-R Related Protein)